Which of the following are typical clinical manifestations of systemic lupus erythematosus: erosive arthritis, proteinuria, seizures or psychotic episodes, hyperparathyroidism, or Coombs‑positive hemolytic anemia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: October 5, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question

Clinical Manifestations of Systemic Lupus Erythematosus

The typical clinical presentations of SLE include proteinuria (b), seizures or psychotic episodes (c), and Coombs-positive hemolytic anemia (e), while erosive arthritis (a) is NOT a typical feature and hyperparathyroidism (d) is NOT associated with SLE.

Analysis of Each Option

a) Erosive Arthritis - NOT TYPICAL

SLE-related arthritis has been traditionally defined as non-erosive and remains a distinguishing feature from rheumatoid arthritis. While recent imaging studies have shown that up to 40% of SLE patients with joint involvement can develop erosive damage, this represents an atypical, more aggressive phenotype rather than a classic presentation 1. The arthritis in SLE is characteristically non-deforming and non-erosive, which helps differentiate it from RA.

b) Proteinuria - TYPICAL ✓

Proteinuria is a hallmark manifestation of lupus nephritis, which represents one of the most serious organ manifestations of SLE. Proteinuria serves as both a diagnostic indicator and a surrogate marker for disease activity with significant prognostic value 2. Renal involvement occurs commonly in SLE, and even patients with low-level proteinuria (<0.5 g/24h) can have significant renal pathology, including proliferative lupus nephritis classes 3. This makes proteinuria a critical clinical feature to monitor.

c) Seizures or Psychotic Episodes - TYPICAL ✓

Neuropsychiatric manifestations are well-established features of SLE, with seizures being among the common manifestations (cumulative incidence >5%) 4. Psychosis is classified as relatively uncommon (1-5% cumulative incidence) but is a recognized NPSLE manifestation 4. Both seizures and psychosis are specifically mentioned as indications for glucocorticoid and immunosuppressive therapy when they reflect an inflammatory process 5, 4. These neuropsychiatric features occur in 30-40% of SLE patients overall, with most events occurring at disease onset or within the first year 4.

d) Hyperparathyroidism - NOT ASSOCIATED

Hyperparathyroidism is not a recognized clinical manifestation of SLE. This option represents a distractor with no pathophysiological connection to lupus.

e) Coombs-positive Hemolytic Anemia - TYPICAL ✓

Autoimmune hemolytic anemia (AIHA) is a recognized hematological manifestation of SLE that frequently necessitates anti-inflammatory/immunosuppressive treatment 5. The positive Coombs test and autoimmune hemolytic anemia were significantly more common in early SLE compared to SLE-mimicking conditions 6. AIHA in SLE is associated with increased risk of thrombocytopenia 7, and its treatment follows established protocols using glucocorticoids, immunosuppressive drugs, and rituximab 5.

Key Clinical Pearls

  • Hematological abnormalities (including Coombs-positive hemolytic anemia, leukopenia, lymphopenia, thrombocytopenia) are prominent early indicators of SLE 8
  • Non-erosive arthritis remains the classic articular presentation, distinguishing SLE from RA
  • Proteinuria warrants aggressive monitoring and renal biopsy even at lower levels (<0.5 g/24h) given the potential for significant underlying lupus nephritis 3
  • Neuropsychiatric manifestations require careful attribution to exclude mimics (infections, malignancy) before attributing to SLE 5, 4

References

2
Research

Urine Protein Tests in Lupus: What do They Mean?

The Journal of rheumatology, 2025

3
Research

Levels of Proteinuria and Renal Pathology in Systemic Lupus Erythematosus Patients.

Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia, 2023

Related Questions

Which of the following are features of systemic lupus erythematosus: pleuritis, non‑scarring alopecia, Raynaud's phenomenon, erosive joint lesions, or photosensitivity with disease flares after sun exposure?
What does proteinuria look like to the naked eye?
Which of the following statements are true for systemic lupus erythematosus: a) erythrocyte sedimentation rate (ESR) and elevated C‑reactive protein (CRP) may coexist, b) antinuclear antibody (ANA) negative with anti‑Sm antibody positive, c) thrombocytopenia, d) leukopenia, e) neutropenia?
What are the common clinical manifestations of systemic lupus erythematosus (SLE)?
How should trace proteinuria be evaluated and managed in a pediatric patient?
How should I dose gentamicin (or amikacin) for a 63‑year‑old woman weighing 56 kg with impaired renal function (serum creatinine ≈2.2 mg/dL) when therapeutic drug monitoring is unavailable?
For a 63-year-old woman weighing 56 kg with impaired renal function (serum creatinine ~2.2 mg/dL), how many days should gentamicin be administered and what dosing interval should be used?
What is the differential diagnosis for a 24-year-old woman with anxiety who presents with a normal lipid panel, mildly elevated aspartate aminotransferase (AST), normal alanine aminotransferase (ALT) at the upper limit of normal, normal fasting glucose, normal eosinophil count, leukopenia, mild anemia with microcytosis, and pruritus of the external ear canal?
I have had recurrent Candida vaginitis for over a year, recently developed a fish‑like odor, vulvar fissures and an abscess on the labia minora, was treated with secnidazole, and now have thick white discharge with severe vaginal and anal pain—what is the appropriate evaluation and management?
A patient with HbA1c 8.4% is taking metformin 850 mg three times daily and gliclazide 30 mg daily; should the gliclazide dose be increased as the next step?
What is the indication for low‑dose aspirin in patients with polycythemia (especially polycythemia vera) who have no contraindications to antiplatelet therapy?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.